Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

About VarmX

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio

News & events

All news
  • Conferences & Events

VarmX team attending JP Morgan Healthcare Week

Leiden, The Netherlands, 10 December 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral...

  • Conferences & Events

VarmX to present at the American Society of Hematology (ASH) Annual Meeting & Exposition

Oral and poster presentations on key VMX-001 data in San Diego from 7-10 December Leiden, The Netherlands, 3 December 2024...

All news